We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
Lexology logo






  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 23

Indian Supreme Court rules for cancer pills patent to be made available to generics

  • King & Wood Mallesons
  • -
  • India
  • -
  • April 29 2013

Earlier this month, the Supreme Court of India dismissed an appeal brought by Novartis against the Indian Intellectual Property Board's 2009 decision

Experimental evidence comply with the rules or risk inadmissibility

  • King & Wood Mallesons
  • -
  • Australia
  • -
  • March 22 2013

By refusing to allow Generic Health to adduce experimental evidence in a patent case currently being heard in the Federal Court, Justice Jagot has

Blockbuster drug goes bust? The Federal Court finds three AstraZeneca patents relating to Crestor (rosuvastatin) invalid

  • King & Wood Mallesons
  • -
  • Australia
  • -
  • March 7 2013

In an important decision handed down on Tuesday, Justice Jagot of the Federal Court held that three patents relating to the blockbuster drug Crestor

Homeopathy plus! Not immune from the ACL

  • King & Wood Mallesons
  • -
  • Australia
  • -
  • March 7 2013

On 21 February 2013, the ACCC instituted proceedings against Homeopathy Plus! Australia Pty Ltd ("Homeopathy Plus!") in the Federal Court of

Australian court decides important gene patenting question isolated genetic material patentable subject matter

  • King & Wood Mallesons
  • -
  • Australia
  • -
  • February 15 2013

Earlier today, the Federal Court rejected a claim brought by Cancer Voices Australia that isolated genetic material (DNA or RNA) that is naturally

In the blue corner FTC comes out swinging on product switching

  • King & Wood Mallesons
  • -
  • USA
  • -
  • January 24 2013

Out-manoeuvring generic competitors is big business for originators in the pharmaceutical industry, but the US Federal Trade Commission (FTC) has

Those drugs cost how much?? Chemist warehouse price list misleading but not for the reasons you might think

  • King & Wood Mallesons
  • -
  • Australia
  • -
  • October 29 2012

Last Monday the Supreme Court of Queensland held that a price list published by various Chemist Warehouse pharmacies in Cairns, Nerang, Coolangatta and other parts of Queensland was likely to mislead or deceive and therefore contravene clause 18 of the Australian Consumer Law (Competition and Consumer Act 2010 (Cth), schedule 2, section 18

India Supreme Court to rule on evergreening clause

  • King & Wood Mallesons
  • -
  • India
  • -
  • September 14 2012

"Evergreening" refers to various legal and commercial strategies employed by companies to maximise profits and frustrate competition, such as making relatively minor changes to existing drugs with soon-to-expire patents in order to obtain further patent protection

Are genes patentable? US Court of Appeals says “yes” for the second time

  • King & Wood Mallesons
  • -
  • USA
  • -
  • August 23 2012

In March this year, the US Court of Appeals was ordered by the US Supreme Court to reconsider its decision in Association for Molecular Pathology v Myriad Genetics

European Commission ups the cost of paying for delay

  • King & Wood Mallesons
  • -
  • Australia, European Union, USA
  • -
  • August 13 2012

On 25 July 2012, the EC alleged that Danish pharmaceutical company Lundbeck violated EU antitrust rules by colluding to prevent other pharma companies from marketing generic versions of its best-seller antidepressant, citalopram

Current Search

Suggested Facets

Author

Jurisdiction

Workarea

© Copyright 2006-2013 Globe Business Publishing Ltd | Cookies | Disclaimer | Privacy policy